{"id":"replagal-agalsidase-alfa","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108214","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fabry disease is caused by deficiency of the lysosomal enzyme α-galactosidase A, leading to accumulation of the glycosphingolipid globotriaosylceramide (GL-3) in multiple tissues. Agalsidase alfa is a recombinant form of this enzyme that, when infused intravenously, enters cells and catalyzes the breakdown of GL-3, reducing pathological accumulation and halting or slowing disease progression. This enzyme replacement therapy addresses the underlying enzymatic defect in Fabry disease.","oneSentence":"Agalsidase alfa is a recombinant human enzyme that replaces deficient α-galactosidase A, breaking down accumulated globotriaosylceramide in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:41.561Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Fabry disease (α-galactosidase A deficiency)"}]},"trialDetails":[{"nctId":"NCT03566017","phase":"PHASE3","title":"Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-09-16","conditions":"Fabry Disease","enrollment":97},{"nctId":"NCT06328608","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-07-29","conditions":"Fabry Disease","enrollment":22},{"nctId":"NCT05710692","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease","status":"RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-08-01","conditions":"Fabry Disease","enrollment":16},{"nctId":"NCT07465562","phase":"NA","title":"Galactol® Enzyme Supplement for Post-Prandial Abdominal Bloating in Irritable Bowel Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Liaquat University of Medical & Health Sciences","startDate":"2026-03-16","conditions":"Irritable Bowel Syndrome, Abdominal Bloating","enrollment":300},{"nctId":"NCT05280548","phase":"PHASE3","title":"A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-05-03","conditions":"Fabry Disease","enrollment":104},{"nctId":"NCT00196742","phase":"","title":"Fabry Disease Registry & Pregnancy Sub-registry","status":"RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2001-07-31","conditions":"Fabry Disease","enrollment":9000},{"nctId":"NCT07109375","phase":"","title":"Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Italia","startDate":"2026-04","conditions":"Fabry Disease","enrollment":75},{"nctId":"NCT05843916","phase":"PHASE3","title":"Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease","status":"COMPLETED","sponsor":"Bio Sidus SA","startDate":"2022-12-13","conditions":"Fabry Disease","enrollment":20},{"nctId":"NCT02956954","phase":"NA","title":"Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-03-25","conditions":"Anderson-Fabry Disease","enrollment":26},{"nctId":"NCT04281537","phase":"","title":"A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2020-03-01","conditions":"Fabry Disease","enrollment":82},{"nctId":"NCT03614234","phase":"PHASE3","title":"Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-11-13","conditions":"Fabry Disease","enrollment":29},{"nctId":"NCT07187440","phase":"","title":"A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-11-01","conditions":"Fabry Disease","enrollment":200},{"nctId":"NCT06880250","phase":"","title":"Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease","status":"ENROLLING_BY_INVITATION","sponsor":"NPO Petrovax","startDate":"2025-03-24","conditions":"Fabry Disease","enrollment":100},{"nctId":"NCT07277361","phase":"","title":"Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment","status":"RECRUITING","sponsor":"Wladimir MAUHIN, Dr","startDate":"2024-10-08","conditions":"Fabry Disease, Aged 65 Years or Older, Alpha Galactosidase A Deficiency","enrollment":100},{"nctId":"NCT07235709","phase":"","title":"Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2025-11-12","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT05067868","phase":"PHASE4","title":"A Study of Replagal in Children and Adults With Fabry Disease in India","status":"RECRUITING","sponsor":"Shire","startDate":"2022-11-01","conditions":"Fabry Disease","enrollment":5},{"nctId":"NCT05039866","phase":"","title":"Long-Term Follow-up of Subjects Who Were Treated With ST-920","status":"ENROLLING_BY_INVITATION","sponsor":"Sangamo Therapeutics","startDate":"2021-08-16","conditions":"Fabry Disease, Fabry Disease, Cardiac Variant","enrollment":48},{"nctId":"NCT06869499","phase":"NA","title":"Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"Wladimir MAUHIN, Dr","startDate":"2025-05","conditions":"Splenomegaly, Splenectomy, Thrombopenia","enrollment":200},{"nctId":"NCT04046224","phase":"PHASE1, PHASE2","title":"Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)","status":"COMPLETED","sponsor":"Sangamo Therapeutics","startDate":"2019-07-23","conditions":"Fabry Disease","enrollment":33},{"nctId":"NCT06052800","phase":"","title":"Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-09-13","conditions":"Fabry Disease","enrollment":78},{"nctId":"NCT06630312","phase":"EARLY_PHASE1","title":"Glycemic Response of Whole Beans and Bean Products","status":"COMPLETED","sponsor":"Iowa State University","startDate":"2023-03-28","conditions":"Healthy, Body Mass Index, Normal, Postprandial Hyperglycemia","enrollment":21},{"nctId":"NCT04974749","phase":"PHASE3","title":"A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-05-01","conditions":"Fabry Disease","enrollment":20},{"nctId":"NCT04840667","phase":"PHASE3","title":"A Study of Replagal in Treatment-naïve Adults With Fabry Disease","status":"TERMINATED","sponsor":"Shire","startDate":"2021-12-28","conditions":"Fabry Disease","enrollment":17},{"nctId":"NCT04943991","phase":"NA","title":"Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wuerzburg University Hospital","startDate":"2021-07-01","conditions":"Fabry Disease, Fabry Disease, Cardiac Variant, Lysosomal Storage Diseases","enrollment":200},{"nctId":"NCT02800070","phase":"PHASE1","title":"Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2016-07","conditions":"Fabry Disease","enrollment":5},{"nctId":"NCT00230607","phase":"PHASE4","title":"Study of the Effects of Fabrazyme Treatment on Lactation and Infants","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-05-28","conditions":"Fabry Disease, Alpha Galactosidase A Deficiency","enrollment":7},{"nctId":"NCT01374997","phase":"NA","title":"Detection of Fabry Disease in Chronic Renal Failure Patients in Area Provence - Alpes - Côte d'Azur","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-06","conditions":"Fabry Disease","enrollment":6},{"nctId":"NCT01981720","phase":"PHASE1, PHASE2","title":"Extension Study of PRX-102 for up to 60 Months","status":"COMPLETED","sponsor":"Protalix","startDate":"2014-01-16","conditions":"Fabry Disease","enrollment":15},{"nctId":"NCT02795676","phase":"PHASE3","title":"Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function","status":"COMPLETED","sponsor":"Protalix","startDate":"2016-06","conditions":"Fabry Disease","enrollment":78},{"nctId":"NCT01678898","phase":"PHASE1, PHASE2","title":"Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients","status":"COMPLETED","sponsor":"Protalix","startDate":"2012-10","conditions":"Fabry Disease","enrollment":18},{"nctId":"NCT03018730","phase":"PHASE3","title":"Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)","status":"COMPLETED","sponsor":"Protalix","startDate":"2017-05-17","conditions":"Fabry Disease","enrollment":22},{"nctId":"NCT03180840","phase":"PHASE3","title":"Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks","status":"COMPLETED","sponsor":"Protalix","startDate":"2017-07-10","conditions":"Fabry Disease","enrollment":30},{"nctId":"NCT04143958","phase":"PHASE4","title":"To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease","status":"WITHDRAWN","sponsor":"Sanofi","startDate":"2020-09","conditions":"Fabry Disease","enrollment":""},{"nctId":"NCT05520411","phase":"NA","title":"Examining the Effectiveness of Digestive Enzymes at Reducing Bloating and Stomach Distension","status":"COMPLETED","sponsor":"HUM Nutrition, Inc.","startDate":"2022-07-01","conditions":"Stomach Distended, Bloating","enrollment":25},{"nctId":"NCT04965467","phase":"","title":"Fabry Aim Children Early (ACE) Project","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2021-07-27","conditions":"Fabry Disease","enrollment":""},{"nctId":"NCT00084084","phase":"PHASE2","title":"Replagal Enzyme Replacement Therapy for Children With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2004-06-10","conditions":"Fabry Disease","enrollment":17},{"nctId":"NCT01304277","phase":"PHASE2","title":"This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.","status":"COMPLETED","sponsor":"Shire","startDate":"2011-11-17","conditions":"Fabry Disease","enrollment":17},{"nctId":"NCT03230591","phase":"","title":"Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2017-07-12","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT00864851","phase":"PHASE3","title":"Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2008-12-29","conditions":"Fabry Disease","enrollment":44},{"nctId":"NCT01363492","phase":"PHASE2","title":"Safety Study of Replagal® Therapy in Children With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2011-05-12","conditions":"Fabry Disease","enrollment":15},{"nctId":"NCT01124643","phase":"PHASE3","title":"Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2010-04-13","conditions":"Fabry Disease","enrollment":35},{"nctId":"NCT01298141","phase":"PHASE3","title":"A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2011-08-10","conditions":"Fabry Disease","enrollment":171},{"nctId":"NCT01031173","phase":"","title":"Treatment Protocol of Replagal for Patients With Fabry Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Shire","startDate":"","conditions":"Fabry Disease","enrollment":""},{"nctId":"NCT01268241","phase":"","title":"The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease","status":"COMPLETED","sponsor":"CENTOGENE GmbH Rostock","startDate":"2010-12","conditions":"Fabry Disease, Fabry´s Disease, Anderson-Fabry Disease","enrollment":200},{"nctId":"NCT01355146","phase":"","title":"Home Therapy With Replagal in Fabry Disease","status":"COMPLETED","sponsor":"Shire","startDate":"2011-03-15","conditions":"Fabry Disease","enrollment":127},{"nctId":"NCT01196871","phase":"PHASE2","title":"Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2011-02-02","conditions":"Fabry Disease","enrollment":20},{"nctId":"NCT01218659","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Amicus Therapeutics","startDate":"2011-09-08","conditions":"Fabry Disease","enrollment":68},{"nctId":"NCT02969200","phase":"","title":"Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance","status":"COMPLETED","sponsor":"Ulla Feldt-Rasmussen","startDate":"2015-04","conditions":"Fabry Disease","enrollment":52},{"nctId":"NCT02908724","phase":"","title":"Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy","status":"COMPLETED","sponsor":"Ulla Feldt-Rasmussen","startDate":"2014-11","conditions":"Fabry Disease","enrollment":66},{"nctId":"NCT03596398","phase":"","title":"Epidemiological Study of Fabry Disease in Taiwan Young Stroke Patients","status":"UNKNOWN","sponsor":"Chiayi Christian Hospital","startDate":"2016-01-01","conditions":"Fabry Disease","enrollment":1000},{"nctId":"NCT02930655","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2015-02-01","conditions":"Fabry Disease","enrollment":14},{"nctId":"NCT01019629","phase":"","title":"Fabry Screening Study","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2009-01-29","conditions":"Fabry Disease","enrollment":2724},{"nctId":"NCT02921620","phase":"PHASE3","title":"Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease","status":"WITHDRAWN","sponsor":"Protalix","startDate":"2017-07","conditions":"Fabry Disease","enrollment":""},{"nctId":"NCT02995993","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Greenovation Biotech GmbH","startDate":"2016-11","conditions":"Fabry Disease","enrollment":6},{"nctId":"NCT00106912","phase":"","title":"Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2005-03-28","conditions":"Fabry Disease","enrollment":35},{"nctId":"NCT00001491","phase":"","title":"Analysis of the Nervous System in Patients With Fabry's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"1995-05-11","conditions":"Fabry's Disease","enrollment":325},{"nctId":"NCT02649660","phase":"","title":"Lipidomics and Functional Analyses of Platelets in Fabry Disease","status":"UNKNOWN","sponsor":"Spital Linth","startDate":"2015-10","conditions":"Fabry Disease","enrollment":32},{"nctId":"NCT01745185","phase":"","title":"Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta","status":"COMPLETED","sponsor":"O & O Alpan LLC","startDate":"2012-06","conditions":"Fabry Disease","enrollment":30},{"nctId":"NCT02843334","phase":"","title":"Study of the Prevalence of Fabry Disease in French Dialysis Patients","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2016-05","conditions":"Fabry Disease, End Stage Renal Disease, Renal Dialysis","enrollment":6000},{"nctId":"NCT01295008","phase":"","title":"Androgenetic Alopecia in Fabry Disease","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2010-12","conditions":"Fabry Disease","enrollment":107},{"nctId":"NCT00196716","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2003-06","conditions":"Fabry Disease","enrollment":21},{"nctId":"NCT00081497","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-01","conditions":"Fabry Disease","enrollment":67},{"nctId":"NCT00068107","phase":"PHASE2","title":"Dosing Study of Replagal in Patients With Fabry Disease","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2003-09","conditions":"Fabry Disease","enrollment":13},{"nctId":"NCT01483287","phase":"EARLY_PHASE1","title":"The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in Irritable Bowel Syndrome (IBS)","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2011-11","conditions":"Irritable Bowel Syndrome","enrollment":20},{"nctId":"NCT01997489","phase":"PHASE4","title":"Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2001-09","conditions":"Fabry Disease","enrollment":39},{"nctId":"NCT01650779","phase":"PHASE4","title":"A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2012-04","conditions":"Fabry Disease","enrollment":15},{"nctId":"NCT01632111","phase":"","title":"Pulmonary Involvement in Patients With Fabry Disease","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2012-07","conditions":"Fabry Disease","enrollment":110},{"nctId":"NCT00312767","phase":"PHASE4","title":"A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.","status":"WITHDRAWN","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-04","conditions":"Fabry Disease","enrollment":""},{"nctId":"NCT01304875","phase":"","title":"Pulmonary Disease and Exercise Tolerance in Boys With Fabry Disease","status":"UNKNOWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2010-04","conditions":"Fabry Disease","enrollment":20},{"nctId":"NCT00357786","phase":"PHASE1","title":"An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-10","conditions":"Fabry Disease","enrollment":3},{"nctId":"NCT01243853","phase":"NA","title":"Alpha-galactosidase Enzyme and Irritable Bowel Syndrome","status":"UNKNOWN","sponsor":"Verman Oy Ab","startDate":"2010-12","conditions":"Irritable Bowel Syndrome","enrollment":150},{"nctId":"NCT00881322","phase":"NA","title":"A Study on Intestinal Gas Symptoms to Evaluate the Effects of Gas Defense in Otherwise Healthy Adult","status":"COMPLETED","sponsor":"Miami Research Associates","startDate":"2008-06","conditions":"Abdominal Pain, Abdominal Cramps, Flatulence","enrollment":61},{"nctId":"NCT00075244","phase":"PHASE2","title":"Alternative Dosing and Regimen of Replagal to Treat Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-01","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT00048906","phase":"PHASE2","title":"Alpha-Galactosidase A Replacement Therapy for Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-11","conditions":"Fabry Disease","enrollment":3},{"nctId":"NCT00071877","phase":"PHASE2","title":"An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-10","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT00097890","phase":"PHASE4","title":"Replagal Enzyme Replacement Therapy for Adults With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-11","conditions":"Fabry Disease","enrollment":25},{"nctId":"NCT00030134","phase":"","title":"Data Collection in Women With Fabry Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-01","conditions":"Fabry Disease","enrollment":60},{"nctId":"NCT00487630","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-06","conditions":"Fabry Disease","enrollment":34}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"INFUSION RELATED REACTION"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PYREXIA"},{"count":1,"reaction":"ANAPHYLACTIC REACTION"},{"count":1,"reaction":"ANGIOKERATOMA"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"BODY TEMPERATURE INCREASED"},{"count":1,"reaction":"C-REACTIVE PROTEIN INCREASED"},{"count":1,"reaction":"CARDIAC DISORDER"},{"count":1,"reaction":"CHILLS"}],"_approvalHistory":[],"publicationCount":244,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["agalsidase alfa"],"phase":"marketed","status":"active","brandName":"Replagal (agalsidase alfa)","genericName":"Replagal (agalsidase alfa)","companyName":"Shire","companyId":"shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"Replagal (agalsidase alfa) is a hydrolytic enzyme used to treat Fabry Disease, specifically targeting the breakdown of globotriosylceramide. It belongs to the class of hydrolytic enzymes and works by hydrolyzing globotriosylceramide.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}